← Back to Search

Monoamine Oxidase Inhibitor

Rasagiline for Parkinson's Disease (PD-SOAR Trial)

Phase 4
Waitlist Available
Led By Grace S Liang, MD
Research Sponsored by The Parkinson's Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 10 weeks
Awards & highlights

PD-SOAR Trial Summary

A decrease or loss of the sense of smell is very common in patients with Parkinson's Disease even in the earliest stages of the disease. There have been no treatments that have been proven to improve sense of smell in patients with Parkinson's Disease. Rasagiline (brand name: Azilect) was approved by the U.S. Food and Drug Administration (FDA) on May 16th 2006 to be used by Parkinson's patients to treat the motor symptoms associated with the disease. The purpose of this study is to see if there is change in sense of smell after starting Rasagiline.

Eligible Conditions
  • Parkinson's Disease

PD-SOAR Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~10 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 10 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change from baseline in UPSIT score at 10-week visit
Secondary outcome measures
Safety: AE incidence
Tolerability: Number of subjects (%) who discontinue the study due to AEs

PD-SOAR Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: RasagilineActive Control1 Intervention
0.5mg of Rasagiline for 14 days, then switch to 1mg of Rasagiline for remainder of the study (approximately 10 weeks total).
Group II: PlaceboPlacebo Group1 Intervention
0.5mg of placebo for 14 days, then switch to 1mg of placebo for remainder of the study (approximately 10 weeks total)

Find a Location

Who is running the clinical trial?

The Parkinson's InstituteLead Sponsor
4 Previous Clinical Trials
14,241 Total Patients Enrolled
Teva Neuroscience, Inc.Industry Sponsor
16 Previous Clinical Trials
5,521 Total Patients Enrolled
Grace S Liang, MDPrincipal InvestigatorThe Parkinson's Institute

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Study Assessing Change in Sense of Smell After Rasagiline Use in Parkinson's Patients
Grace Liang 2009. "A Study Assessing Change in Sense of Smell After Rasagiline Use in Parkinson's Patients". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01007630.
All > Parkinson
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top